Evidence map›Paper›PMID 28757102›Full record

ArticleBioorganic & medicinal chemistry2017

New prodrugs of two pyrimidine acyclic nucleoside phosphonates: Synthesis and antiviral activity.

Marcela Krečmerová, Martin Dračínský, Robert Snoeck, Jan Balzarini, Karel Pomeisl, Graciela Andrei

Open access · greenAbstract read
In one paragraph

Article in Bioorganic & medicinal chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. COVID-19 therapy: What weapons do we bring into battle?Bioorganic & medicinal chemistry · 2020
    Article
  6. Article
  7. Article
  8. An improved synthesis of adefovir and related analogues.Beilstein journal of organic chemistry · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Marcela KrečmerováInstitute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Flemingovo nám. 2, CZ-166 10, Prague 6, Czech Republic. Electronic address: marcela@uochb.cas.cz.
Martin DračínskýInstitute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Flemingovo nám. 2, CZ-166 10, Prague 6, Czech Republic.
Robert SnoeckRega Institute for Medical Research, KU Leuven, Herestraat 49, Box 1043, B-3000 Leuven, Belgium.
Jan BalzariniRega Institute for Medical Research, KU Leuven, Herestraat 49, Box 1043, B-3000 Leuven, Belgium.
Karel PomeislInstitute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Flemingovo nám. 2, CZ-166 10, Prague 6, Czech Republic.
Graciela AndreiRega Institute for Medical Research, KU Leuven, Herestraat 49, Box 1043, B-3000 Leuven, Belgium. Electronic address: graciela.andrei@kuleuven.ac.be.
Czech Academy of Sciences, Institute of Organic Chemistry and Biochemistry · CZKU Leuven · BERega Institute for Medical Research · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

New 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidine (PMEO-DAPy) and 1-[2-(phosphonomethoxy)ethyl]-5-azacytosine (PME-5-azaC) prodrugs were prepared with a pro-moiety consisting of carbonyloxymethyl esters (POM, POC), alkoxyalkyl esters, amino acid phosphoramidates and/or tyrosine. The activity of the prodrugs was evaluated in vitro against different virus families. None of the synthesized prodrugs demonstrated activity against RNA viruses but some of them proved active against herpesviruses [including herpes simplex virus (HSV), varicella-zoster virus (VZV), and human cytomegalovirus (HCMV)]. The bis(POC) and the bis(amino acid) phosphoramidate prodrugs of PMEO-DAPy inhibited herpesvirus replication at lower doses than the parent compound although the selectivity against HSV and VZV was only slightly improved compared to PMEO-DAPy. The mono-octadecyl ester of PME-5-azaC emerged as the most potent and selective PME-5-azaC prodrug against HSV, VZV and HCMV with EC

Indexed as

Antiviral AgentsCell LineCytomegalovirusHerpesvirus 3, HumanHumansOrganophosphonatesProdrugsPyrimidine NucleosidesSimplexvirusAntiviral AgentsOrganophosphonatesProdrugsPyrimidine Nucleosides5-AzacytosineAcyclic nucleoside phosphonatesAntiviralsHPMP-5-azaCOpen-ringPhosphonatePME-azaCPMEO-DAPyProdrug

Identifiers

PMID28757102
PMCPMC7126465
OpenAlexW2733799892

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.